Level D· Scientific groundwork from lab and animal studiesAnimal StudyPubMed

Evaluation of an experimental therapy based on bovine mesenchymal stem cell (MSC) secretome for the treatment of endometritis in dairy cows.

Díaz C., Frankenberg D., Retamal P., Escobar C., Morera FJ., Paiva L.

Animal Study on Immune Modulation, published in Sci Rep (2025) — summary generated from the PubMed abstract.

Open my reading list
Level D· Scientific groundwork from lab and animal studiesEvidence level of this study

Evidence from laboratory and animal studies provides groundwork for understanding mechanisms and potential before human studies continue.

  • Level A · Stronger Clinical Evidence
  • Level B · Emerging clinical evidence with positive signals
  • Level C · Early human research exploring benefits
  • Level D · Scientific groundwork from lab and animal studies
  • Emerging · Emerging topic under active research
Read the A–D evidence level guide

This page is generated from the PubMed record. The Thai description is an automated summary of bibliographic fields and the abstract, not a full translation, and is not medical advice.

Study type
Animal Study
Journal
Sci Rep (2025)
Country
England
Reported sample size
—
Source database
PubMed
PMID
41381608
DOI
10.1038/s41598-025-27499-4

Abstract (original English)

Endometritis impairs uterine function and reduces reproductive performance in dairy cows. Conventional treatment involves intrauterine antibiotics; however, antimicrobial resistance has become an increasing concern worldwide. Biofactors secreted by mesenchymal stem/stromal cells (MSCs), collectively known as the secretome possess immunomodulatory, anti-apoptotic, angiogenic, and antimicrobial properties and may represent a novel alternative for treating bovine endometritis. This study evaluated the in vitro antimicrobial potential of bovine fetal MSC-derived secretome (sMSC) against Escherichia Coli and assessed the safety and efficacy of sMSC-based therapy in dairy cows. Conditioned media (CM) derived from fetal bone marrow (BM) and adipose tissue (AT) MSCs reduced E. Coli survival by up to 98%. Intrauterine administration of sMSC produced no significant clinical or hematological alterations, demonstrating that the treatment is safe. Cows with clinical endometritis receiving two intrauterine doses of lyophilized sMSC, separated by 14 days, showed lower (P < 0.05) endometrial polymorphonuclear (PMN) counts (~ 47%) and postpartum endometritis grade (EG) (~ 78%) than placebo-treated animals (PCB). Proteomic analysis of lyophilized sMSC revealed that 11% of the total protein content corresponded to secreted protein acidic and cysteine rich (SPARC), a molecule with known roles in t

What this study does not prove

  • • This study does not prove SVF is an approved treatment or a replacement for standard care.
  • • This is preclinical work; animal or laboratory results cannot be applied to humans.

Evidence level

Evidence from laboratory and animal studies provides groundwork for understanding mechanisms and potential before human studies continue.

How we grade evidence
AnimalsCattleFemaleEndometritisMesenchymal Stem CellsSecretomeCattle DiseasesEscherichia coliCulture Media, ConditionedMesenchymal Stem Cell Transplantation

Browse all related research

Filter the research library by this study's title keywords, author, or publication year.

Related research